A Near-Full ‘Strawberry Moon' Will Shine Again on Wednesday Night
Night sky observers are being treated this week to a view of a red-tinted full moon — known in June as a 'strawberry moon' — a phenomenon that occurs when the moon sits low on the Southern Horizon.
This summer, the reddish color is particularly pronounced because the moon is sitting at the lowest position it will reach for about 19 years.
The strawberry moon's colorful hues were visible Tuesday night, and it reached its brightest point Wednesday around 4 a.m. Eastern time.
Here's what it looked like:
Each month's full moon has a name.
According to folklore, the name 'strawberry moon' came from Algonquin Native American tribes to commemorate strawberry gathering season. Another name for the full moon in June is 'rose moon,' which may have come from Europe.
'Most of the traditional names we use seem to come from Native American usage, but some are clearly European in origin, like the one in December, called 'the moon before yule,' a reference to Christmas,' said James Lattis, a historian of astronomy at the University of Wisconsin-Madison.
The moon will not sit this low on the Southern Horizon again for about 19 years.
Summer full moons are always low relative to winter full moons in the Northern Hemisphere, and therefore are more reddish in color, Dr. Lattis said. That's because viewing the moon through the atmosphere gives it a reddish hue, much like the colors visible during a sunrise or sunset, he said.
'If one looks straight up into the sky, there's less atmosphere,' he said. 'If you're looking through the horizon, you're looking through the most atmosphere.'
The strawberry moon will still be 'visually full' for observers on Wednesday night.
Dr. Lattis said that he had viewed the moon on Tuesday night in Wisconsin, and that it was notable for the pinkish hue it had from smoke in the air from wildfires. He said the sight may not be as dramatic elsewhere.
'I hate to discourage anybody from going out and looking at the moon — it's a wonderful thing to do, and a lot of times, if you don't give somebody a reason, they'll never do it,' he said. 'But it's just another full moon.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Geek Wire
17 minutes ago
- Geek Wire
Seattle's Allen Institute launches ‘moonshot' to create new approach to cell biology research
A cross-section image of cells forming a hollow sphere, called a lumenoid. The colors mark different proteins expressed by the cells inside and outside of the sphere. (Allen Institute Image) Human cells, like the people they create, are dynamic and complex. And while researchers can create images and videos of how they move, organize and change their properties, it's hard to efficiently and accurately describe all that's happening. So a 75-person team at Seattle nonprofit Allen Institute is embarking on a 10-year project called CellScapes to devise a new language using mathematics to capture these essential processes. 'This is a new way of approaching very fundamental cell biology,' Ru Gunawardane, executive director and vice president of the Allen Institute for Cell Science, told GeekWire. 'We want to combine math and biophysical modeling, which are things that people are doing right now, but in a siloed way in very different systems.' Ru Gunawardane, executive director and vice president of the Allen Institute for Cell Science. (Allen Institute Photo) The Allen Institute was founded more than 20 years ago by the late Microsoft co-founder Paul Allen and his sister Jody Allen to dive into challenging problems in the biosciences. Previous efforts at multiple institutions have created numerical systems for understanding biological processes. That includes BayesSpace, a computational tool that produces data on gene expression in mixed cell types that developed researchers at the Fred Hutch Cancer Center. The Allen Institute has engineered modeling for organelles, which are the various machines packed inside cells that make proteins, produce energy and perform other key operations. 'The exciting thing is that we are trying … to bring different disciplines together,' Gunawardane said, 'because data is everywhere — but how do you make sense out of that data?' The CellScapes researchers are working with human stem cells, which are cells that don't yet have a set identity as, say, a skin or liver cell. The hope is through analysis and experimentation they'll devise mathematics that describe the cell's behavior, ultimately allowing them to predict and manipulate what the cells do. A primary goal would be to use these tools to unravel mysteries such as the intermediate steps to developing cancer, and ultimately discover new cell therapies. 'It's a lot like astronomy and going from 'which planet is that dot in the sky' to 'what are the laws of motion that describe all moving objects?'' said Wallace Marshall, professor of biochemistry and biophysics at the University of California, San Francisco, and a CellScapes advisor, in a statement. The Allen Institute seen from Dexter Yard. (GeekWire File Photo / Charlotte Schubert) The Allen Institute will make its data and innovations in the space publicly available, Gunawardane said, and expects to collaborate with researchers at outside institutions. The research team includes software engineers, computational biologists, program managers and others. There is no set budget for the decade-long effort, and the CellScapes team is simultaneously pursuing three projects that are part of the broader initiative. The effort already has a scientific paper accepted by the journal Nature that will be published in coming months. It's an exciting time, Gunawardane said. 'I also feel a huge responsibility,' she said, 'because Paul [Allen] is not alive anymore, but our work is his legacy, and he asked us to break the code of the cell. And in a way, the code is very complicated — it's more like a program, the cellular program. 'So I feel like we are now actually at the brink,' she said, 'of knowing maybe how to approach that.'
WebMD
22 minutes ago
- WebMD
FDA OKs New Next-Gen Pill for Rare Lung Cancer
approved a first-of-its-kind oral pill to treat a rare type of advanced lung cancer that often spreads to the brain. The new drug, known as taletrectinib but sold as Ibtrozi, is meant for adults with non-small-cell lung cancer (NSCLC) that has spread or worsened and is linked to a faulty ROS1 gene. This targeted therapy offers new hope to about 3,000 people in the U.S. and over 1 million globally who are diagnosed each year with advanced ROS1-positive NSCLC. NSCLC is the most common form of lung cancer – a leading cause of cancer-related deaths. About 2% of advanced cases are ROS1-positive, which grow faster and are harder to treat. Most patients are diagnosed in their 50s, often without a history of smoking. The cancer often spreads to the brain, seen in 35% at diagnosis and nearly 50% after treatment. This makes treatment especially challenging and highlights the need for better options. The FDA's decision was based on two clinical studies of people with ROS1-positive NSCLC. One trial involved 113 people who had previously been treated with a drug similar to Ibtrozi, while the other included 157 who had not. About 85% to 90% of those new to treatment responded to Ibtrozi, and at least 63% continued to see benefits for over a year. Among those previously treated, about 52% to 62% improved, with most (up to 83%) continuing to respond for at least six months. Ibtrozi also helped shrink brain tumors in 73% of people who were new to similar treatments, and in 63% of those who had tried one before, according to a news release by Nuvation Bio, the drug's maker. "Ibtrozi's durability of response and ability to effectively penetrate the brain, coupled with a well-characterized and manageable safety profile, further addresses these critical needs for patients," said Nathan Pennell, MD, PhD, a professor of medicine at the Cleveland Clinic and an investigator of the clinical trials. Ibtrozi belongs to a class of medicines called tyrosine kinase inhibitors (TKIs). It blocks the faulty ROS1 protein, helping slow cancer growth and spread. Ibtrozi is designed to reach the brain and keep the disease under control for longer. The FDA recommends 600 mg oral Ibtrozi pills once a day on an empty stomach, with no food two hours before or after taking it. Treatment continues until the cancer worsens or side effects become too serious. The most common side effects include things like nausea, diarrhea, tiredness, and dizziness. The FDA also warns about more serious risks, like liver and lung problems, heart rhythm issues, muscle pain, and possible harm to an unborn baby. People who use the drug should tell their doctor about all medications they're taking, including over-the-counter ones – especially anything for acid reflux. Women are advised not to breastfeed during treatment and for three weeks afterward. It's also important to protect your skin from the sun while taking the drug and for at least five days after stopping it.
Health Line
44 minutes ago
- Health Line
Are Biomarker Testing and Genetic Testing the Same Thing?
Biomarker testing and genetic testing have different purposes in diagnosing colorectal cancer. The first helps doctors understand cancer's growth and spread, while the second assesses a person's inherited risk. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. It's sometimes referred to as 'colon cancer' or 'rectal cancer,' depending on the area it first develops. According to the American Cancer Society, more than 150,000 new cases of colorectal cancer are expected in 2025. It's one of the top causes of cancer-related death, while the overall risk of developing CRC for people assigned male at birth is about 1 in 24, and 1 in 26 for those assigned female at birth. Despite being one of the most common cancers globally, survival rates for CRC have improved in many parts of the world due to medical advancements in biomarker testing and genetic testing. Both biomarker testing and genetic testing in CRC involve screening for genetic mutations, but these tests have distinct purposes during the diagnosis process. You'll notice that the language used to share stats and other data points is pretty binary, fluctuating between the use of 'male' and 'female' or 'men' and 'women.' Although we typically avoid language like this, specificity is key when reporting on research participants and clinical findings. The studies and surveys referenced in this article didn't report data on or include participants who were transgender, nonbinary, gender nonconforming, genderqueer, agender, or genderless. What is biomarker testing? Biomarker testing in medicine is used to assess, predict, or monitor disease progression. Biomarkers (biological markers) are measurable biological processes, molecules, and cellular changes that provide insight into what's happening in your body at an exact moment. The presence or absence of biomarkers or their changes provides important insight into a developing or progressing medical condition. In CRC, biomarker testing, also called 'tumor testing,' is performed on cancer cells to look for tumor-specific changes. It detects the presence of acquired genetic mutations (somatic mutations), cellular changes, and DNA changes in cancer that could influence its growth and spread. CRC biomarkers can relay information about your overall outlook and whether CRC may be responsive to certain treatments more than others. What is genetic testing? Genetic testing is a specific type of biomarker testing that analyzes your DNA to determine your risk of cancer. In CRC, genetic testing looks for inherited genetic mutations or variants (called germline mutations) associated with an increased risk of CRC. Genetic testing is mainly used as a form of risk assessment. Doctors perform these tests if you have a family history of CRC or meet the criteria for an inherited cancer syndrome. If you've received a diagnosis of CRC and didn't undergo genetic testing first, your doctor may still recommend testing after a diagnosis in certain instances. These include when there's a family history of CRC or if the disease appears to follow a hereditary pattern of development. Types of testing There are several types of tests doctors run when assessing biomarkers and genetic risk in CRC, including: Single gene: This looks for an isolated gene. Panel test: This screens multiple genes at once. Whole-genome sequencing: This assesses all the DNA in a cell. Whole-exome sequencing: This screens only the components in a gene responsible for protein coding. Tumor-mutational burden: This determines the overall number of genetic changes in a tumor's DNA. Common tumor biomarkers Biomarker testing in CRC screens for various measurable tumor indicators, including genetic mutations, protein expression levels, signaling molecules, DNA sequencing patterns, antigens, and more. Common CRC tumor biomarkers your doctor may test for include: MSI-H/dMMR sidedness (which side of the colon the cancer is located on) KRAS NRAS BRAF HER2 EGFR CEA TRK fusions DPD ctDNA PD-L1 pathway WNT pathway RET VEGF CTC MMR deficiency Common genetic tests Genetic testing for CRC typically includes screening for genetic mutations relating to inherited cancer syndromes such as: Lynch syndrome familial adenomatous polyposis (FAP) MUTYH-associated polyposis Peutz-Jeghers syndrome These are inherited conditions that significantly increase your risk of developing CRC. Genes that may be screened in genetic testing for CRC risk include: MLH1 MSH2 MSH3 MSH6 PMS2 APC MUTYH POLE POLD1 NTHL1 GREM1 RNF43 (primarily used in research) RPS20 (primarily used in research) Benefits of testing Genetic testing and biomarker testing in CRC are part of precision medicine and can help improve your cancer outcomes. Genetic testing before a potential cancer diagnosis allows you and your doctor to understand your individual risk for CRC. Knowing your likelihood can help you take preventive steps to lower your overall risk of cancer and can help detect cancer in its earliest, most treatable stages. If you've received a CRC diagnosis, biomarker testing reveals details about the disease that help your doctor treat it with the most effective therapies right from the start. Certain biomarkers, for example, can indicate if CRC will be responsive to immunotherapy or monoclonal antibody therapy. Other biomarkers can help predict treatment response and monitor recurrence. Qualification criteria Anyone with a CRC diagnosis is a candidate for biomarker testing to help direct treatment planning, but not everyone requires genetic testing to determine their inherited risk. Genetic testing is typically recommended when: you have a family history of CRC or a hereditary cancer syndrome in more than one biological relative you received a CRC diagnosis before the age of 50 CRC was diagnosed in a first-degree relative younger than age 50 multiple family members have received a diagnosis of another type of cancer associated with hereditary cancer syndromes (like ovarian or stomach cancer) you've received a diagnosis of two or more primary types of cancer biomarker testing suggests a germline mutation you have a significant number of colorectal polyps How to talk with your doctor Anyone can develop CRC, so the United States Preventive Services Task Force (USPSTF) recommends screening for all adults ages 45 and over. However, you don't have to wait until you are 45 to talk with your doctor about CRC, especially if you have a family history of the condition or inherited cancer syndromes. To help make the most of this conversation with your doctor, consider these tips: Research CRC and learn as much as you can before your appointment. Talk with your parents and biological family members to verify your family medical history. Bring a written list of questions. Have a friend or loved one come with you for support and another perspective. Take notes on what your doctor says to review at home. If you've already had biomarker testing or genetic testing for CRC, questions that may be helpful to ask your doctor include: Which genes and biomarkers were tested for? Did my tests show any biomarkers or inherited mutations? What do the results of my tests mean for my CRC risk or treatment planning? Were all possible biomarkers tested for? If not, why? Will more genetic or biomarker testing be necessary?
